Legend Biotech Corp
Legend Biotech Corp (LEGN): 8 pipeline candidates · ~255 mo cash runway · 9 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
255.2 months
D/E 0.73 · 0% dilution
Lead: Phase 2
8 candidates
N/A
0 buys · 1 sell (180d)
A transparent, data-derived signal for Legend Biotech Corpacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$6.3B
Cash
$948.6M
Quarterly Burn
$12.2M
Runway
255.2 mo
Revenue
$306.5M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| LB1908 | Phase 1 |
| LB2102 | Phase 1 |
| LCAR- F33S cells intravenous infusion | — |
| LCAR-AIO T cells | Phase 1 |
| LCAR-B38M CAR-T Cell | Phase 2 |
| LUCAR-DKS1 NK cells | Phase 1 |
| LUCAR-G79 T cells | Phase 1 |
| LUCAR-G79D T cells | Phase 1 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
189
Total value held
$1.57B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 25,696,740 | $464.9M |
| deerfield management company, l.p. | 7,687,638 | $139.1M |
| suvretta capital management, llc | 7,581,029 | $137.1M |
| hhlr advisors, ltd. | 5,984,550 | $108.3M |
| westfield capital management co lp | 5,763,475 | $104.3M |
| blackrock, inc. | 4,684,543 | $84.7M |
| two sigma investments, lp | 1,890,396 | $34.2M |
| kynam capital management, lp | 1,576,295 | $28.5M |
| state street corp | 1,498,372 | $27.1M |
| goldman sachs group inc | 1,464,112 | $26.5M |
Showing top 10 of 189 institutional holders of Legend Biotech Corp. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Legend Biotech Corp's pipeline?
Legend Biotech Corp (LEGN) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Legend Biotech Corp's lead drug candidate?
Legend Biotech Corp's most advanced tracked candidate is LB1908 (Phase 1) for Gastric Cancer.
What is Legend Biotech Corp's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Legend Biotech Corp has approximately 255.2 months of cash runway.
What is Legend Biotech Corp's market capitalization?
Legend Biotech Corp's market capitalization is approximately $6.3B.
Who is the CEO of Legend Biotech Corp?
Dr. Ying Huang Ph.D. is the chief executive officer of Legend Biotech Corp (LEGN).
Get the full picture on Legend Biotech Corp
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.